Cite
HARVARD Citation
Ikezawa, Y. et al. (2022). Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression. Cancer science. 113 (6), pp. 2109-2117. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ikezawa, Y. et al. (2022). Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression. Cancer science. 113 (6), pp. 2109-2117. [Online].